Michael Sawyer

Professor, Faculty of Medicine & Dentistry - Oncology Dept

Contact

Professor, Faculty of Medicine & Dentistry - Oncology Dept
Email
msawyer@ualberta.ca
Phone
(780) 432-8248
Address
Cross Cancer Institute
11560 University Avenue
Edmonton AB
T6G 1Z2

Overview

Area of Study / Keywords


About

Academic Interests
Translational cancer research, Phase I studies/Drug Development, Clinical Pharmacology of Anticancer Drugs, and Pharmacogenetics
 
Clinical Practice
Gastrointestinal Malignancies, Neuroendocrine Tumors, Phase I Studies

Research

Clinical Trials Research:
My interest in clinical trials is focused on gastrointestinal malignancies and neuroendocrine tutors. Along with Quincy Chu, we are establishing a phase I program at the Cross Cancer Institute.

Fundamental/Translational Research:
My focus is on of anticancer drugs. My research interests and collaborations are broad but are unified by the common thread of trying to understand causes of interpatient variability in terms of toxicity and efficacy. My major interest is understanding mechanisms of nephrotoxicity of chemotherapy especially antifolates and nucleoside analogues. My major collaborator in this research is Carol E. Cass, an international expert in nucleoside transport and therapeutics. Pharmacogenetics is another major interest that I developed during my training with M. Ratain. I am interested in the roles that polymorphisms play in the interpatient variation in drug elimination. I am also interested in the role that nutrition plays in the toxicity and efficacy of chemotherapy and have developed extensive collaborations with Drs. Vickie Baracos and Catherine Field. The research has been supported by the Alberta Cancer Board, Alberta Cancer Foundation, The Canadian Breast Cancer Foundation, The Canadian Breast Cancer Research Alliance and the Canadian Institutes of Health Research. I have received funding from Hoffman La Roche, Pfizer and .

 

Featured Publications

Annual Meeting of American Society of Clinical Oncology. 2022 June; 10.1200/JCO.2022.40.16_suppl.3573


Cancer Res (2022) 82 (12_Supplement): CT006. 2022 June; 10.1158/1538-7445.AM2022-CT006


Annual Meeting of the American Society of Clinical Oncology. 2022 June; 10.1200/JCO.2022.40.16_suppl.3614


Abdel-Rahman O., Pham T.M., Pokhrel A., Ruether D., Sawyer M.B.

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS. 2022 May; 45 (5):208-214 10.1097/COC.0000000000000906


Youn S., Eurich D.T., McCall M., Walker J., Smylie M., Sawyer M.B.

CLINICAL NUTRITION. 2022 May; 41 (5):1066-1072 10.1016/j.clnu.2022.03.001


Giani J., Chambers C.R., Sawyer M.B.

JOURNAL OF ONCOLOGY PHARMACY PRACTICE. 2022 March; 28 (2):457-461 10.1177/10781552211038031


Youn S., Jogiat U., Baracos V.E., McCall M., Eurich D.T., Sawyer M.B.

Clinical Nutrition ESPEN. 2021 October; 45 10.1016/j.clnesp.2021.06.029


Joy A.A., Vos L.J., Pituskin E., Cook S.F., Bies R.R., Vlahadamis A., King K., Basi S.K., Meza-Junco J., Mackey J.R., Stanislaus A., Damaraju V.L., Damaraju S., Sawyer M.B.

Clinical Breast Cancer. 2021 October; 21 (5):e584-e593 10.1016/j.clbc.2021.03.001


Youn S., Chen A., Ha V., Chambers C., Eurich D.T., McCall M., Sawyer M.B.

CLINICAL NUTRITION. 2021 August; 40 (8):4888-4892 10.1016/j.clnu.2021.06.026


Phase I study of H3B-6527 in hepatocellular carcinoma (HCC) or intrahepatic cholangiocarcinoma (ICC)

Journal of Clinical Oncology, 2021. 39(15_suppl): p. 4090-4090.. 2021 June;


Damaraju V.L., Aminpour M., Kuzma M., Winter P., Preto J., Tuszynski J., McEwan A.B.J., Sawyer M.B.

CTS-Clinical and Translational Science. 2021 May; 14 (3):847-858 10.1111/cts.12943


Youn S., Reif R., Chu M.P., Smylie M., Walker J., Eurich D.T., Ghosh S., Sawyer M.B.

EUROPEAN JOURNAL OF CLINICAL NUTRITION. 2021 April; 42 10.1016/j.clnesp.2021.01.009


Sarcopenia predicts dose-limiting toxicity in pancreatic cancer treated with nab-paclitaxel and gemcitabine

American Association of Cancer Researchers Annual Meeting 2021. 2021 April;


Giani J., Sawyer M.B., Chambers C.

JOURNAL OF ONCOLOGY PHARMACY PRACTICE. 2021 March; 27 (2):447-479 10.1177/1078155220934163


Nath E., Sawyer M.B., Choy J.

Case Reports in Oncology. 2021 January; 13 (3):1454-1462 10.1159/000511414


Ford K.L., Sawyer M.B., Trottier C.F., Ghosh S., Deutz N.E.P., Siervo M., Porter Starr K.N., Bales C.W., Disi I.R., Prado C.M.

Clinical Nutrition ESPEN. 2021 January; 41 10.1016/j.clnesp.2020.11.016


Sarcopenia predicts dose-limiting toxicity in pancreatic cancer treated with nab-paclitaxel and gemcitabine

13th international SCWD digital conference on cachexia, sarcopenia and muscle wasting. 2020 December;


van der Meij B.S., Teleni L., Stanislaus A.E., Murphy R.A., Robinson L., Damaraju V.L., Chu Q., Sawyer M.B., Mazurak V.

Clinical Nutrition ESPEN. 2020 November; 40 10.1016/j.clnesp.2020.09.009